Gamma Knife Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

The global Gamma Knife market is projected to grow significantly, reaching a value of USD 301 million by 2032, up from USD 205 million in 2025. This growth reflects a strong CAGR of 5.64% during the forecast period. The market is being propelled by increasing cases of neurological disorders, the growing preference for minimally invasive surgeries, and rapid technological advancements in radiosurgery systems.

Market Insights

Gamma Knife radiosurgery is a precise, non-invasive form of radiation therapy used primarily to treat conditions affecting the brain. This procedure uses highly focused gamma radiation beams to target tumors and other abnormalities, eliminating the need for surgical incisions and offering a faster recovery time for patients. The procedure is most commonly used in the treatment of brain metastases, arteriovenous malformations, trigeminal neuralgia, and other complex neurological conditions.

A key advantage of Gamma Knife technology is its ability to treat affected areas with minimal impact on surrounding healthy tissues. This feature has contributed to a higher adoption rate, especially among elderly patients and those who are not ideal candidates for traditional surgery.

Market Drivers

The growing elderly population worldwide has led to a rising prevalence of neurological conditions, including brain tumors, Parkinson’s disease, Alzheimer’s disease, and epilepsy. As these conditions continue to increase, the demand for effective, low-risk treatment options such as Gamma Knife radiosurgery is growing rapidly.

Brain metastases, in particular, are becoming more common, especially among cancer patients in advanced stages. Clinicians are increasingly turning to Gamma Knife radiosurgery due to its precision, fewer side effects, and ability to treat multiple lesions in a single session. Additionally, combination treatments that integrate immunotherapy with Gamma Knife radiosurgery are showing promising results, further fueling market growth.

Business Opportunities

As awareness grows regarding the benefits of non-invasive procedures, developing economies are showing greater interest in adopting Gamma Knife technologies. The introduction of next-generation devices with enhanced treatment planning, remote accessibility, and improved patient comfort is expanding the market Analysis.

Moreover, new product launches and strategic collaborations by key players are opening new avenues. For instance, Elekta’s launch of the Esprit system in 2022 represents a leap forward in personalized radiosurgery, combining advanced imaging and faster treatment planning for better outcomes.

Regional Analysis

The United States continues to dominate the global Gamma Knife market, driven by a high prevalence of cancer and neurological disorders. The country’s robust healthcare infrastructure and growing patient awareness are supporting the adoption of Gamma Knife procedures.

Germany is emerging as a promising market, primarily due to the rising incidence of Alzheimer’s disease and other cognitive disorders. Investments in healthcare innovation and government support for medical research are aiding the market’s development in the region.

Japan is also seeing steady growth, supported by an increase in vascular abnormalities and significant technological upgrades within the healthcare sector. The country’s emphasis on precision medicine and minimally invasive treatments is reinforcing the adoption of Gamma Knife technologies.

Key Players

Key companies in the Gamma Knife market are focusing on expanding their global presence through product innovation, partnerships, and regulatory approvals. Leading players include:
• Elekta AB
• Varian Medical Systems
• Huiheng Medical, Inc.
• MASEP Medical Science Technology Development (Shenzhen) Co., Ltd.
• Akesis Inc.
• Cyber Medical Corporation Limited
• Masep Infini Global, Inc.
• Nordion, Inc.
• Hokai
• ET Medical Group
• American Shared Hospital Services

These companies are at the forefront of technological advancements and continue to develop solutions that improve treatment efficacy and patient experience.

Market Segmentation

By Disease Indication:
• Brain Metastasis
• Cancer
• Arteriovenous Malformation (AVM)
• Trigeminal Neuralgia
• Others

By Organ Treated:
• Head
• Neck
• Others

By Region:
• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa

Please note: Delivery Timelines - 5 working days. Show more